- TSX-V:UVC
A Generational Opportunity in a $248B Market
Delivering 70× superior pathogen reduction in a $248B market, Illumisoft combines a validated IP moat with an attractive valuation gap against legacy competitors to redefine global biological safety.
Exchange
TSX-V: UVC
Why Invest
Four compelling reasons why Illumisoft represents a unique investment opportunity in the infection prevention space.
The Market Arbitrage
Illumisoft offers a compelling entry at ~$7.8M USD post-money. Compare this to R-Zero, who raised $170M USD using conventional UVC technology. We offer superior technology at approximately 4% of their implied valuation.
$248B
Market 2024
$473B
Market 2034
9.9%
HAI CAGR
IP & Clinical Validation
Our portfolio is defended by 19+ patents. University of Leeds validated as “best performing UV device tested.” Our breakthrough Far-UVC technology is validated to be 70× more powerful in pathogen reduction while remaining safe for human occupancy.
19+
Patents
99.7%
Kill Rate
70×
More Powerful
The Execution Engine
We hold the First Health Canada Registration for an upper-room GUV device. This regulatory first-mover advantage streamlines our path to FDA 510(k) and CE Marking while achieving 60% gross margins.
60%
Gross Margin
24
Day Payback
1st
HC Approval
Path to Liquidity
Phase 1 commercialization targets 6,500 hospitals in North America. Key catalysts include TSX-V listing, Tier-1 hospital contracts, and FDA 510(k) filing. Establishing Far-UVC as critical building infrastructure.
$248B
Market 2024
$473B
Market 2034
9.9%
HAI CAGR
Market Size
The global infection control market is experiencing unprecedented growth, driven by regulatory changes and heightened awareness of indoor air quality.
$248B
Global Infection Control Market (2024)
$473B
Projected Market Size (2034)
$38.5B
HAI Control Market (Immediate TAM)
6.7%
Market CAGR Growth Rate
The Opportunity
Canada has the worst HAI rate in the OECD at 10.5% vs. 3% best practice. The consequences are catastrophic: 4,000+ deaths in Ontario LTC facilities alone, over $1 billion in combined lawsuits, and $29.3B in annual costs.
Canada responded by becoming the first nation to mandate engineered infection prevention standards through CSA Z8000:24 and CSA Z317.12:25.
Illumisoft is the only Canadian company with Health Canada-registered technology positioned to capture this market.
Annual HAIs in Canada
473,590
Annual Deaths
33,151
Annual Economic Cost
$29.3B
30-Year ROI
44,741%
Backed By Visionaries
Mission-aligned investors committed to transforming global public health through breakthrough technology.
“The pandemic exposed the critical need for effective indoor air disinfection. Illumisoft's technology represents a real breakthrough that could fundamentally change how we protect indoor spaces.”
“Far-UVC is one of the most important public health innovations of our time. Illumisoft is leading the charge with technology that makes practical what was previously impossible.”
Strategic Ownership
19.43%
Held via
Resilience Reserve LLC
Chris Anderson (TED) · Rob Reid
Documents
Access our latest investor materials, financial reports, and corporate documents.
Latest corporate deck with company overview, technology, and investment thesis.
Download →Quarterly and annual financial statements and MD&A.
Coming soonUniversity of Leeds study and technical documentation for the SaniLume 254 nm GUV platform.
Download →Corporate governance policies and committee charters.
Coming soon